KLK3 and cancer: Cancer adapts to a low testosterone environment, leading to a clinical state called castration-resistant prostate cancer (CRPC), characterized by an androgen-independent phenotype with a limited response to ADT, visceral and bone metastases, and relatively low levels of prostate-specific antigen (PSA) [4].